Details of the Drug

General Information of Drug (ID: DMG02ET)

Drug Name
KP-1461
Synonyms KP1461; 943540-08-7; C522536000
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 2 [1]
Pneumococcal infection CA00-CA40 Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C16H28N4O6
Canonical SMILES
CCCCCCCOC(=O)NC1=NCN(C(=O)N1)C2CC(C(O2)CO)O
InChI
InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1
InChIKey
SZWIAFVYPPMZML-YNEHKIRRSA-N
Cross-matching ID
PubChem CID
51003457
CAS Number
815588-85-3
UNII
3PEN569TJP
DrugBank ID
DB05644
TTD ID
D0X0FU
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT00504452) Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients. U.S. National Institutes of Health.